Journal
JOURNAL OF INFECTION
Volume 74, Issue -, Pages S143-S146Publisher
W B SAUNDERS CO LTD
DOI: 10.1016/S0163-4453(17)30205-0
Keywords
Respiratory syncytial virus; Vaccines; Live attenuated vaccines; Virus vectored vaccines; Virus fusion protein
Categories
Funding
- Wellcome Trust [203077] Funding Source: Medline
Ask authors/readers for more resources
2017 will mark the 60th anniversary since the first isolation of RSV in children. In spite of concerted efforts over all these years, the goal of developing an effective vaccine against paediatric RSV disease has remained elusive. One of the main hurdles standing in the way of an effective vaccine is the fact that the age incidence of severe disease peaks within the first 3 months of life, providing limited opportunity for intervention. In addition to this complexity, the spectre of failed historical vaccines, which increased the risk of illness and death upon subsequent natural infection, has substantially increased the safety criteria against which modern vaccines will be assessed. This review traces the history of RSV vaccine development for young infants and analyses the potential reasons for the failure of historic vaccines. It also discusses recent breakthroughs in vaccine antigen design and the progressive evolution of platforms for the delivery of these antigens to seronegative infants. (C) 2017 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available